Effect of Aprepitant on Pharmacokinecics of Controlled-Release Oxycodone

Effect of Aprepitant on Pharmacokinecics of Controlled-Release Oxycodone - Effect of Aprepitant on Pharmacokinecics of Controlled-Release Oxycodone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003580

Enrollment

Registered

2010-06-01

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients receiving controlled-release oxycodone

Interventions

Pharmacokinetics of oxycodone and its metabolites with and without aprepitant administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with malignant solid tumors or hematological malignancy 2. age > 18 years 3. Patients receiving aprepitant for the prevention of chemotherapy induced nausea and vomiting. 4. Adequate hepatic and renal function 5. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients requiring rescue use of Oxynorm 2. Concomitant medications of CYP3A4 strong inhibitors or inducers 3. Patients with malabsorption 4. Patients judged inappropriate for the study by the physicians

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of oxycodone and its metabolites with and without aprepitant administration	—

Secondary

Measure	Time frame
Safety, Adverse event, Effectiveness	—

Countries

Japan

Contacts

Public ContactYutaka Fujiwara

Department of Medicine, Kobe University Hospital and Graduate School of Medicine Medical Oncology/Hematology

fu_ji_@yahoo.co.jp0783825111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026